Hyperurikämie, Gicht und Herz – eine kritische Diskussion im Licht der aktuellen Literatur

Zusammenfassung

Zahlreiche Untersuchungen zeigen, dass Patienten mit Hyperurikämie und insbesondere mit symptomatischer Hyperurikämie, einer Gicht, kardiovaskuläre Risikopatienten sind. Bei symptomatischer Hyperurikämie sollte nach aktuellen Leitlinien eine harnsäuresenkende Therapie mit Zielwert-Erreichung eingeleitet werden. Darüber hinaus sind die Diagnose und optimale Therapie der klassischen kardiovaskulären Risikofaktoren von besonderer Bedeutung.

Abstract

Numerous studies show that patients with hyperuricemia, especially those with symptomatic hyperuricemia (gout), are cardiovascular risk patients. In the case of symptomatic hyperuricemia, current guidelines recommend that uric acid-lowering therapy should be initiated as part of a treat-to-target strategy. In addition, it is of central importance for the cardiovascular risk factors to be diagnosed and treated effectively as recommended by current guidelines. New therapeutic approaches like low-dose colchicine have yielded encouraging results in recent studies.

Schlüsselwörter

Gicht - Kristallarthritis - Harnsäure - Herz - Leitlinie

Key words

gout - urate - crystal arthropathies - heart - guideline

Publication History

Article published online:
16 February 2021

• Literatur

• 1 Engel B, Just J, Bleckwenn M. et al. Treatment Options for Gout. Dtsch Arztebl Int 2017; 114: 215-222
• 2 Reis LN, Borfe L, Brand C. et al. Food Consumption is Associated with Hyperuricemia in Boys. High Blood Press Cardiovasc Prev 2020; 27: 409-415
• 3 Skoczyńska M, Chowaniec M, Szymczak A. et al. Pathophysiology of hyperuricemia and its clinical significance – a narrative review. Reumatologia 2020; 58: 312-323
• 4 Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 2020; 12: 3167-3181
• 5 Borghi C, Agabiti-Rosei E, Johnson RJ. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 2020; 80: 1-11
• 6 Zhang S, Wang Y, Cheng J. et al. Hyperuricemia and Cardiovascular Disease. Curr Pharm Des 2019; 25: 700-709
• 7 Kim H, Kim SH, Choi AR. et al. Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study. Medicine (Baltimore) 2017; 96: e6565
• 8 Packer M. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors. J Card Fail 2020; 26: 977-984
• 9 Andrés M, Bernal JA, Sivera F. et al. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis 2017; 76: 1263-1268
• 10 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
• 11 Jaeschke L, Steinbrecher A, Greiser KH. et al. Assessment of self-reported cardiovascular and metabolic diseases in the German National Cohort (GNC, NAKO Gesundheitsstudie): methods and initial results. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 439-451
• 12 Tausche AK, Manger B, Müller-Ladner U, Schmidt B. Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia Z Rheumatol 2012; 71: 224-230
• 13 Aringer M, Hedrich C, Tausche AK. Inflammasome and gout. Z Rheumatol 2016; 75: 537-541
• 14 Silvis MJM, Demkes EJ, Fiolet ATL. et al. Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. J Cardiovasc Transl Res 2020; Epub ahead of print. PMID: 32648087
• 15 Hansildaar R, Vedder D, Baniaamam M. et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 2020; Epub ahead of print. PMID: 32904897; PMCID: PMC7462628
• 16 Clarson LE, Chandratre P, Hider SL. et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2015; 22: 335-343
• 17 Disveld IJM, Fransen J, Rongen GA. et al. Janssens HJEM, Janssen M. Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease. J Rheumatol 2018; 45: 858-863
• 18 Richette P, Doherty M, Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42 209707
• 19 Kiltz U, Alten R, Fleck M. et al. [Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF]. Z Rheumatol 2017; 76: 118-124
• 20 Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410
• 21 Niskanen LK, Laaksonen DE, Nyyssönen K. et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-1551
• 22 Anker SD, Doehner W, Rauchhaus M. et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107: 1991-1997
• 23 Kim SY, Guevara JP, Kim KM. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-892
• 24 Ridker PM, Everett BM, Thuren T. et al. CANTOS Trial Group Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377: 1119-1131
• 25 Nidorf SM, Fiolet ATL, Mosterd A. et al. LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383: 1838-1847
• 26 Bouabdallaoui N, Tardif JC, Waters DD. et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020; 41: 4092-4099
• 27 Mahmoud AN, Gad MM, Elgendy AY. et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 2019; 40: 607-617
• 28 Lee SJ, Terkeltaub RA. New developments in clinically relevant mechanisms and treatment of hyperuricemia. Curr Rheumatol Rep 2006; 8: 224-230
• 29 Waldman B, Ansquer JC, Sullivan DR. et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol 2018; 6: 310-318
• 30 Kim HS, Kim H, Lee SH. et al. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia. J Clin Pharm Ther 2020; 45: 1264-1270
• 31 Selvaraj S, Claggett BL, Pfeffer MA. et al. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail 2020; 22: 2093-2101
• 32 Bruderer S, Bodmer M, Jick SS. et al. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014; 66: 185-196
• 33 Fralick M, Chen SK, Patorno E. et al. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med 2020; 172: 186-194 Epub 2020 Jan 14. PMID: 31931526; PMCID: PMC7217750
• 34 White WB, Saag KG, Becker MA. et al. CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018; 378: 1200-1210
• 35 Mackenzie IS, Ford I, Nuki G. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020; 396: 1745-1757
• 36 Pirlamarla P, Bond RM. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med 2016; 26: 675-680